

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Robert J. Hariri

Confirmation No.: 6313

**Application No.: 10/721,144** 

Group Art Unit: 1632

Filing Date: November 25, 2003

**Examiner: Not Yet Assigned** 

For: CYTOTHERAPEUTICS, CYTOTHERAPEUTIC UNITS AND METHODS

FOR TREATMENTS USING THEM

DATE OF DEPOSIT: Opril 16, 2004

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA,

TYPED NAME: Elizabeth A. McLoud

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

## INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

Ŧ

the above identified application as set forth in § 1.491, before the mail				
of a first Office Action on the merits of the above-identified application, or				
before the mailing date of a first Office Action after the filing of request for				
continued examination under § 1.114, no additional fee is required.				
In accordance with § 1.129(a), this Information Disclosure Statement is being				
filed in connection with  the first or second After Final Submission				
therefore:				
☐ Certif	ication in Accordance with § 1.97(e) is attached; or			
The fe	ee of \$180.00 as set forth in § 1.17(p) is attached.			
In accordance with § 1.97(c), this Information Disclosure Statement is being				
filed after the period	set forth in § 1.97(b) above but before the mailing date of			
either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or				
before an action that otherwise closes prosecution in the application, therefore:				
	Certification in Accordance with § 1.97(e) is attached;			
	or			
	The fee of $$180.00$ as set forth in § 1.17(p) is attached.			
In accordance with	§ 1.97(d), this Information Disclosure Statement is being			
filed after the mailing date of either a Final Action under § 1.113 or a Notice				
of Allowance under § 1.311 but before, or simultaneously with, the payment				
of the Issue Fee, therefore included are: Certification in Accordance with §				
1.97(e); and the subm	nission fee of $$180.00$ as set forth in $$1.17(p)$ .			
Copies of each of the	ne references listed on the attached Form PTO-1449 are			
enclosed herewith.				

DOCKET NO.: ANTH-0004 - 3 -**PATENT** 冈 Copies of references listed on the attached Form PTO-1449 are enclosed herewith 冈 Copies of references listed on the attached Form PTO 1449 are not required to be submitted pursuant to the June 30, 2003 recent revisions to 37 CFR § 1.98(a)(2)(i). **EXCEPT THAT:** 冈 In view of the voluminous nature of reference number 3, and the likelihood that this reference is available to the Examiner, copies are not enclosed herewith. П In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C.§ 120 have been made in the instant application: П Copies of references [list as appropriate] listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. , filed

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

DOCKET NO.: ANTH-0004

-4
PATENT

The relevance of those listed references which are not in the English language is as follows:

There are no listed references which are not in the English language.

Date: Apul 16 2007

Lohn W. Caldwell Registration No. 28,937

WOODCOCK WASHBURN LLP One Liberty Place - 46th Floor Philadelphia, PA 19103 Telephone: (215) 568-3100

Facsimile: (215) 568-3439

© 2004 WW

				· · · · · · · · · · · · · · · · · · ·			
Form PTO-1449 Modified  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office				Docket No. ANTH-0004	1 **		
				Applicant Robert J. Hariri			
				Filing Date November 25, 2003			
				Confirmation No. 6313			
		<b>U.</b> :	S. PATENT	T DOCUMENTS	· · · · · · · · · · · · · · · · · · ·		
Examiner Initial	Document No. Date Name		Class	Subclass			
	4	5,372,581	12/13/94	Anderson	604	32	
	5	5,415,665	05/16/95	Hessel, et al.	606	120	
					:		
				-			
		FORE	IGN PATE	ENT DOCUMENTS		<u>-                                    </u>	
Examiner						Translation	
Initial		Document No.	Date	Country	YES	NO	
	6	WO 02/46373 A1	06/13/02	PCT			
	7	WO 02/064755 A3	08/22/02	PCT		-	
EXAMINER				DATE CONSIDERE		1	



OIPE	
APR 1 9 2004	
PRADEMARKS.	7

Form PT	O-1449 Modified	Docket No. ANTH-0004	Application No. 10/721,144				
Cited	ent and Publications I by Applicant I sheets if necessary)	Applicant Robert J. Hariri					
	tment of Commerce I Trademark Office	Filing Date November 25, 2003	Group 1632				
•		Confirmation No. 6313					
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	Kamarck, M.E., "[14] Fluorescence-activated cell sorting of hybrid and transfected cells," <i>Methods Enzymol.</i> , <b>1987</b> , <i>151</i> , 150-165						
•	2 Keown, W.A., et al., "M Methods in Enzymol., 19	ethods for introducing DNA into mammalian cells," <b>990</b> , 185, 527-537					
*	3 Sambrook, et al., Molecu Harbor Laboratory Pres	ular Cloning, A Laboratory Manual, 3 <sup>rd</sup> Ed., Cold Spring					
EXAMINER		DATE CON	SIDERED				

© 2004 WW

<sup>\*</sup> A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.